Following its latest medical breakthrough whereby treatment of a brain tumor derived from a metastatic esophageal cancer with Cesium-131 was proven successful, IsoRay announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.
Cesium-131 is an exclusive technology from IsoRay, an innovative company developing seed brachytherapy and medical radioisotope applications, which allows for the precise treatment of different types of cancer, since it has a unique blend of high energy and a 9.7-day half-life, making it uniquely fast in giving off therapeutic radiation and one of the most significant advances in internal radiation therapy of the last 20 years.
Dr. Carlos Alvarez, Neurosurgeon at Instituto de Columna y Cerebro in Lima, inserted the world’s first stereotactic brain implant, utilizing Cesium-131 seeds in a 7 year-old female patient who was diagnosed with a 3 centimeter inoperable Glioma brain tumor that was positioned close to the brainstem. “Due to the size and tumor location, surgery and delivering high dose radiation using radiosurgery was not an attractive option,” said Dr. Alvarez.
Furthermore, no postoperative complications were registered, and the young patient was awake with no neurological deficit.
Cesium-131 is FDA-cleared for internal radiation therapy of different types of cancer, such as brain, prostate, lung, colorectal, melanoma and gynecologic cancer, and it can be delivered using several methods such as single seed applicators, implantable strands and seed sutured mesh, and several implantable devices including the GliaSite® radiation therapy system, the world’s only liquid radiation balloon catheter device used in the treatment of brain cancer.
“These cases pull on your heart strings and IsoRay’s team rose again to the challenge in support of physicians worldwide and patients in need. By placing custom made Cesium-131 within the tumor, a very high dose can be delivered while sparing other critical structures in the brain and brainstem. IsoRay’s ability to deliver our isotope required the timely cooperation of Peruvian governmental agencies and our distributor BioProPeru. Thankfully the early reports from Dr. Alvarez are very rewarding to those who worked so hard on this case and we hope for continued success. We are extremely pleased with the exceptional results a growing number of thought leaders and major medical centers are experiencing throughout the U.S. and internationally as Cesium-131 receives more widespread adoption. We believe Cesium-131’s ability to fight cancer with new delivery options while improving the quality of life for the men, women, and children who are battling these devastating cancers distinguishes it from other treatment options,” stated IsoRay CEO Dwight Babcock.
IsoRay wishes to implement Cesium-131 as a standard care for treatment of multiple cancers, hopefully taking on difficult cancers and improving patients’ life quality.
[adrotate group=”1″]
